{"id":702,"date":"2020-05-13T18:12:16","date_gmt":"2020-05-13T18:12:16","guid":{"rendered":"https:\/\/www.pharmity.com\/?p=702"},"modified":"2024-11-03T15:12:40","modified_gmt":"2024-11-03T15:12:40","slug":"validation-and-qualification-of-eclinical-systems-1","status":"publish","type":"post","link":"https:\/\/www.pharmity.com\/validation-and-qualification-of-eclinical-systems-1\/","title":{"rendered":"Validation and Qualification of eClinical Systems (1)"},"content":{"rendered":"\r\n

Based on recent inspection findings, the GCP Inspectors Working Group \u00a0(IWG) and the Committee for Medicinal Products For Human Use (CHMP) recognize the need to emphasize requirements for sponsors\/vendors providing computerised systems or services as well as for the qualification and validation of computerised systems used to manage clinical trial data.<\/span><\/h4>\r\n

<\/p>\r\n

INTRODUCTION<\/strong><\/span><\/h3>\r\n

Acceptance of data from clinical trials for decision-making purposes depends on the Regulatory Authorities\u2019 ability to verify the quality and integrity of the data.<\/span><\/p>\r\n

As explained in this article, data integrity has become a major priority during regulatory inspections.\u00a0 \u00a0Deficiencies on the computerised systems used to generate and handle clinical trials data<\/strong> (moving forward referred to as eClinical systems), compromises not only the data integrity but also the data reliability and robustness. GCP applies to all parties involved in the clinical trial conduct including computerised systems vendors.<\/span><\/p>\r\n

The software used must be in a validated state. If the use of the software involves configuration\/programming for a clinical trial, this must be validated to ensure it is functioning correctly. For example: eCRF (design of entry screen, edit checks, clinical database), IRT (design of randomization and allocation system for IMP for a clinical trial), ePRO (design of entry screens, edit checks, data transfer), statistical package (programming for analysing data).<\/span><\/p>\r\n

A considerable number of software applications are provided by, or purchased from, vendors and are customized to different degrees. Observations are raised during GCP inspections regarding the level of validation\/qualification needed to be performed by a sponsor when using a system that has already been (or is supposed to have been) validated by the supplier.<\/span><\/p>\r\n

The EMA \u201cNotice to sponsors on validation and qualification of computerised systems used in clinical trials<\/em>\u201d published on the 7th<\/sup> of April 2020 reinforces that:<\/span><\/p>\r\n